Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2021

Reconciliation of revenue from segments to consolidated

The following tables present our segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands). Segment information for the years ended December 31, 2020 and 2019 (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 2.


	Evolent Health Services		Clinical Solutions		Intersegment Eliminations		Subtotal		Corporate (1)		Consolidated
Revenue
For the Year Ended December 31, 2021
Transformation services	$	11,204	$	—	$	—	$	11,204	$	—	$	11,204
Platform and operations services	300,423		598,144		(1,814)		896,753		—		896,753
Total revenue	$	311,627	$	598,144	$	(1,814)	$	907,957	$	—	$	907,957


For the Year Ended December 31, 2020
Transformation services	$	11,990	$	—	$	—	$	11,990	$	—	$	11,990
Platform and operations services	373,144		542,279		(2,774)		912,649		—		912,649
Total revenue	$	385,134	$	542,279	$	(2,774)	$	924,639	$	—	$	924,639

For the Year Ended December 31, 2019
Transformation services	$	15,203	$	—	$	—	$	15,203	$	—	$	15,203
Platform and operations services	394,328		278,217		(626)		671,919		—		671,919
Total revenue	$	409,531	$	278,217	$	(626)	$	687,122	$	—	$	687,122

	Evolent Health Services		Clinical Solutions		Subtotal		Corporate (1)		Segments Total
For the Year Ended December 31, 2021
Adjusted EBITDA	$	17,063	$	82,920	$	99,983	$	(33,666)	$	66,317

For the Year Ended December 31, 2020
Adjusted EBITDA	$	57,731	$	26,864	$	84,595	$	(36,022)	$	48,573

For the Year Ended December 31, 2019
Adjusted EBITDA	$	(561)	$	12,523	$	11,962	$	(25,793)	$	(13,831)

————————

(1)Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.

Reconciliation of Adjusted EBITDA to net loss

The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the years ended December 31, 2021, 2020 and 2019 (in thousands):


	For the Year Ended December 31,
	2021		2020		2019
Net loss attributable to common shareholders of Evolent Health, Inc.	$	(37,601)	$	(334,246)	$	(301,971)
Less:
Interest income	407		2,633		3,406
Interest expense	(25,425)		(28,325)		(14,555)
(Provision) benefit for income taxes	(483)		2,368		22,795
Depreciation and amortization expenses	(60,037)		(60,835)		(60,323)
Equity method investment impairment	—		(47,133)		—
Gain on transfer of membership	45,938		—		—
Loss on repayment of debt, net	(21,343)		—		—
Loss on extinguishment of debt	—		(4,789)		—
Goodwill impairment	—		(215,100)		(199,800)
Gain (loss) from equity method investees	13,179		10,039		(9,465)
Gain (loss) on disposal of assets	—		(698)		9,600
Change in fair value of contingent consideration and indemnification asset	(13,281)		(3,860)		3,997
Net loss attributable to non-controlling interests	—		—		3,609
Other income (expense), net	(146)		(118)		(489)
Purchase accounting adjustments	—		—		(1,915)
Repositioning costs	(7,318)		(1,275)		—
Stock-based compensation expense	(16,711)		(14,606)		(15,618)
Severance costs	(198)		(8,986)		(17,350)
Amortization of contract cost assets	(476)		(3,944)		(2,876)
Strategy and shareholder advisory expenses	(6,513)		—		—
Acquisition costs	(4,194)		(2,116)		(10,769)
Gain (loss) from discontinued operations (1)	(7,317)		(6,074)		1,613
Adjusted EBITDA	$	66,317	$	48,573	$	(13,831)

————————

(1)Includes $6.8 million gain on disposal of discontinued operations for the year ended December 31, 2021.